WO1996040944A3 - Fused soluble mhc heterodimer:peptide complexes and their uses - Google Patents

Fused soluble mhc heterodimer:peptide complexes and their uses Download PDF

Info

Publication number
WO1996040944A3
WO1996040944A3 PCT/US1996/010102 US9610102W WO9640944A3 WO 1996040944 A3 WO1996040944 A3 WO 1996040944A3 US 9610102 W US9610102 W US 9610102W WO 9640944 A3 WO9640944 A3 WO 9640944A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide complexes
soluble mhc
mhc heterodimer
fused
fused soluble
Prior art date
Application number
PCT/US1996/010102
Other languages
French (fr)
Other versions
WO1996040944A2 (en
Inventor
Wayne Kindsvogel
Eva Pia Reich
Jane A Gross
Shrinkant Deshpande
Paul O Sheppard
Original Assignee
Zymogenetics Inc
Anergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, Anergen Inc filed Critical Zymogenetics Inc
Priority to JP9502204A priority Critical patent/JPH11507238A/en
Priority to EP96922445A priority patent/EP0833930A2/en
Priority to AU63316/96A priority patent/AU6331696A/en
Publication of WO1996040944A2 publication Critical patent/WO1996040944A2/en
Publication of WO1996040944A3 publication Critical patent/WO1996040944A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Immune modulators, such as soluble, fused MHC heterodimers and soluble, fused MHC heterodimer:peptide complexes, are described. Related methods and peptides are also disclosed. In a preferred aspect, these mediators and methods are related to autoimmunity.
PCT/US1996/010102 1995-06-07 1996-06-07 Fused soluble mhc heterodimer:peptide complexes and their uses WO1996040944A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP9502204A JPH11507238A (en) 1995-06-07 1996-06-07 Fused soluble MHC heterodimer: peptide conjugates and uses thereof
EP96922445A EP0833930A2 (en) 1995-06-07 1996-06-07 Fused soluble mhc heterodimer:peptide complexes and their uses
AU63316/96A AU6331696A (en) 1995-06-07 1996-06-07 Fused soluble mhc heterodimer:peptide complexes and their uses

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US48324195A 1995-06-07 1995-06-07
US48000295A 1995-06-07 1995-06-07
US48213395A 1995-06-07 1995-06-07
US596495P 1995-10-27 1995-10-27
US08/480,002 1995-10-27
US08/483,241 1995-10-27
US08/482,133 1995-10-27
US60/005,964 1995-10-27

Publications (2)

Publication Number Publication Date
WO1996040944A2 WO1996040944A2 (en) 1996-12-19
WO1996040944A3 true WO1996040944A3 (en) 1997-01-23

Family

ID=27485544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/010102 WO1996040944A2 (en) 1995-06-07 1996-06-07 Fused soluble mhc heterodimer:peptide complexes and their uses

Country Status (6)

Country Link
EP (1) EP0833930A2 (en)
JP (1) JPH11507238A (en)
KR (1) KR19990022641A (en)
AU (1) AU6331696A (en)
CA (1) CA2224205A1 (en)
WO (1) WO1996040944A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10503379A (en) * 1994-07-29 1998-03-31 デイド・インターナショナル・インコーポレーテッド MHC complex and use thereof
US7074904B2 (en) 1994-07-29 2006-07-11 Altor Bioscience Corporation MHC complexes and uses thereof
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
NZ507901A (en) * 1998-05-05 2003-06-30 Corixa Corp Isolated myelin basic protein (MBP) for treating mutliple sclerosis
FR2778669B1 (en) * 1998-05-14 2002-06-14 Centre Nat Rech Scient PROCESS FOR EXPRESSING A COMPLEX FORMED OF AT LEAST ONE PRODUCT OF THE MAJOR HISTOCOMPATIBILITY COMPLEX AND A PEPTIDE IN A PHAGE, PHAGES AND COMPLEXES OBTAINED THEREFROM AND THEIR APPLICATIONS
EP1675607B1 (en) 2003-09-05 2015-10-21 Oregon Health & Science University Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
AU2006316036B2 (en) 2005-11-17 2011-12-15 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. A compound comprising an autoantigenic peptide and a carrier with a MHC binding motif
US8491913B2 (en) 2009-03-07 2013-07-23 Oregon Health & Science University Compositions and methods using recombinant MHC molecules for the treatment of stroke
US9260506B2 (en) 2011-04-07 2016-02-16 Oregon Health & Science University Treatment of retinal disorders with recombinant T cell receptor ligand (RTL)
US10316075B2 (en) 2013-10-03 2019-06-11 Oregon Health & Science University Recombinant polypeptides comprising MHC class II α1 domains

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018150A1 (en) * 1991-04-23 1992-10-29 Anergen, Inc. Mhc conjugates useful in ameliorating autoimmunity
WO1994024290A1 (en) * 1993-04-08 1994-10-27 British Bio-Technology Limited Fusion proteins between antigenic amino acid sequences and beta-2-microglobulin
WO1994025054A1 (en) * 1993-04-29 1994-11-10 Andrew Atkin Recombinant vaccine
WO1995023814A1 (en) * 1994-03-04 1995-09-08 National Jewish Center For Immunology And Respiratory Medicine Product and process for t cell regulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018150A1 (en) * 1991-04-23 1992-10-29 Anergen, Inc. Mhc conjugates useful in ameliorating autoimmunity
WO1994024290A1 (en) * 1993-04-08 1994-10-27 British Bio-Technology Limited Fusion proteins between antigenic amino acid sequences and beta-2-microglobulin
WO1994025054A1 (en) * 1993-04-29 1994-11-10 Andrew Atkin Recombinant vaccine
WO1995023814A1 (en) * 1994-03-04 1995-09-08 National Jewish Center For Immunology And Respiratory Medicine Product and process for t cell regulation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
H. KOZONO ET AL.: "Production of soluble MHC class II proteins with covalently bound single peptides.", NATURE, vol. 369, no. 6476, 12 May 1994 (1994-05-12), LONDON, GB, pages 151 - 154, XP002018445 *
J. FAYEN ET AL.: "Soluble human CD8alpha binds to a recombinant fusion protein which incorporates the class I MHC alpha3 domain.", THE JOURNAL OF IMMUNOLOGY, vol. 150, no. 8 part II, 15 April 1993 (1993-04-15), BALTIMORE, MD, USA, pages 288A, XP002018446 *
S. SHARMA ET AL.: "Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 88, no. 24, 15 December 1991 (1991-12-15), WASHINGTON, DC, USA, pages 11465 - 11469, XP002018447 *

Also Published As

Publication number Publication date
CA2224205A1 (en) 1996-12-19
KR19990022641A (en) 1999-03-25
WO1996040944A2 (en) 1996-12-19
AU6331696A (en) 1996-12-30
JPH11507238A (en) 1999-06-29
EP0833930A2 (en) 1998-04-08

Similar Documents

Publication Publication Date Title
CA2290485A1 (en) Method for the production of non-immunogenic proteins
AU4397297A (en) Antibody against human parathormone related peptides
CA2262001A1 (en) Mhc binding peptide oligomers and methods of use
AU2527397A (en) Fas ligand fusion proteins and their uses
AU5159798A (en) Branched peptide linkers
AU6542598A (en) Site protected protein modification
WO1995013297A3 (en) Improved immunogenic compositions against human gastrin 17
EP0676967A4 (en) Readily available konjac glucomannan sustained release excipient.
AU8113591A (en) Coconjugate vaccines comprising immunogenic protein, hiv related peptides, and anionic moieties
AUPN999096A0 (en) Peptides, antibodies, vaccines & uses thereof
WO1996040944A3 (en) Fused soluble mhc heterodimer:peptide complexes and their uses
AU2419595A (en) Recombinant human immunodeficiency virus vector and process for producing the same
AU7454698A (en) Improvement in medicament administration system
AU7638894A (en) B70(b7-2):ctla-4 bonding protein
EP0647239A4 (en) Angiotensin iv peptides and receptor.
PL316590A1 (en) Cosmetic composition based on non-ionic guar gum and not crosslinked anionic polymer
AU5021796A (en) Recombinant human anti-lewis b antibodies
AU7495796A (en) Novel oligopeptides, the preparation and use thereof
AU6301698A (en) Anti-hiv peptides and proteins
EP0887416A3 (en) Human AFC1
AU4347296A (en) Process for preparing aliphatic alpha,omega-aminonitriles in the gaseous phase
AU8030098A (en) Polypeptide presentation system
WO1999011783A3 (en) T-box polypeptides
EP0911391A3 (en) A clone HWHHJ20
AU7497196A (en) Recombinant ligands for the human cell membrane antigen cd30

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 502204

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1019970709216

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2224205

Country of ref document: CA

Ref country code: CA

Ref document number: 2224205

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996922445

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996922445

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019970709216

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1019970709216

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1996922445

Country of ref document: EP